Biogen (BIIB) Stock Falls on Alzheimer's Drug Trial Death Reports
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
Go back to Biogen (BIIB) Stock Falls on Alzheimer's Drug Trial Death Reports
November 28, 2022 9:26 AM EST
Truist Securities analyst Robyn Karnauskas weighed in on Biogen (NASDAQ: BIIB) following recent news of the second death reported for Alzheimer's drug lecanemab. The analyst highlights:
The recent news and AEs of the drug raise lots of questions whether...
More
November 28, 2022 8:51 AM EST
By Peter Nurse
Investing.com -- Stocks in focus in premarket trade on Monday, November 28th. Please refresh for updates.
Apple (NASDAQ: AAPL) stock fell 1.8% after a report indicated the tech giant will see a production shortfall of nearly 6 million iPhone Pro... More
November 28, 2022 7:13 AM EST
Biogen (NASDAQ: BIIB) on watch following cautious report in Science with the headline, "Second death linked to potential antibody treatment for Alzheimers disease."
...
More
November 28, 2022 3:57 AM EST
Biogen (NASDAQ: BIIB) December weekly option implied volatility is at 55, December is at 51; compared to its 52-week range of 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
...
More
November 25, 2022 10:52 AM EST
Biogen (NASDAQ: BIIB) November weekly option implied volatility is at 31, December weekly is at 58, December is at 45; compared to its 52-week range of 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
...
More
November 25, 2022 4:49 AM EST
Biogen (NASDAQ: BIIB) November weekly option implied volatility is at 22, December weekly is at 55, December is at 56; compared to its 52-week range 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
...
More
